DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
OXFORD, United Kingdom, Feb. 23, 2018 -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for rare diseases and infectious diseases, announces that management will participate in one on one meetings at the 2018 BTIG Healthcare Conference on 27 February 2018 in Snowbird, UT, US.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit | ||
| Glyn Edwards / Richard Pye (UK office) | Tel: | 44 (0)1235 443 951 |
| Erik Ostrowski / Michelle Avery (US office) | +1 617 225 4455 | |
| Cairn Financial Advisers LLP (Nominated Adviser) | Tel: | +44 (0)20 7213 0880 |
| Liam Murray / Tony Rawlinson | ||
| N+1 Singer (Joint Broker) | Tel: | +44 (0)20 7496 3000 |
| Aubrey Powell / Jen Boorer | ||
| Panmure Gordon (Joint Broker) | Tel: | +44 (0)20 7886 2500 |
| Freddy Crossley, Corporate Finance | ||
| Tom Salvesen, Corporate Broking | ||
| MacDougall Biomedical Communications (US) | Tel: | +1 781 235 3060 |
| Karen Sharma | [email protected] | |
| Consilium Strategic Communications (UK) | Tel: | +44 (0)20 3709 5700 |
| Mary-Jane Elliott / Jessica Hodgson / | [email protected] | |
| Philippa Gardner / Rosie Phillips |
-END-
